Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Marta Lopez-Yurda"'
Autor:
Irene A. Caspers, Ellis L. Eikenboom, Marta Lopez-Yurda, Nicole C.T. van Grieken, Tanya M. Bisseling, Evelien Dekker, Barbara A.J. Bastiaansen, Annemieke Cats, Monique E. van Leerdam
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102494- (2024)
Summary: Background: Lynch syndrome increases the risk of gastric cancer (GC) and duodenal cancer (DC), particularly in individuals with MLH1 and MSH2 pathogenic variants (PVs). To provide further insight into whether, and from what age, esophagogast
Externí odkaz:
https://doaj.org/article/38d196956e17415f8cb9ac5982794d93
Autor:
Annegien Broeks, Sofie Wilgenhof, John B A G Haanen, Karolina Sikorska, Christian U Blank, Judith M Versluis, Jan Willem B de Groot, Esmee P Hoefsmit, Elisa A Rozeman, Petros Dimitriadis, Aysegul Sari, Daan van den Broek, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Stijn W T P J Heijmink, Marieke A Vollebergh, Johannes V van Thienen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatme
Externí odkaz:
https://doaj.org/article/85f4bb454d4548b7b0eddc4aff9da5e2
Autor:
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed when alectinib minimum plasma con
Externí odkaz:
https://doaj.org/article/4457ff0cdd7b4bd9aa0922759784c7a7
Autor:
Eline A. M. Zijtregtop, Friederike Meyer‐Wentrup, Wai‐Chu Wong, Raoull Hoogendijk, Marta Lopez‐Yurda, Christian M. Zwaan, Auke Beishuizen
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 152-160 (2020)
Abstract Pediatric classical Hodgkin's lymphoma (cHL) is characterized by Hodgkin Reed‐Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active crosstalk between these cells. One promising biomarker in adult
Externí odkaz:
https://doaj.org/article/87c34c5b6f704ee3be92ca0a49c7e344
Autor:
Karen Bolhuis, Iris van 't Erve, Clinton Mijnals, Pien M. Delis – Van Diemen, Joost Huiskens, Aysun Komurcu, Marta Lopez-Yurda, Daan van den Broek, Rutger-Jan Swijnenburg, Gerrit A. Meijer, Cornelis J.A. Punt, Remond J.A. Fijneman
Publikováno v:
EBioMedicine, Vol 70, Iss , Pp 103498- (2021)
Background: Recurrence rates after resection of colorectal cancer liver metastases (CRLM) are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is a promising prognostic biomarker. Focusing on patients with resected
Externí odkaz:
https://doaj.org/article/ac3dfdb0ce244b71940b89028a6d2ade
Autor:
Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Wouter J. Plattel, Franck Morschhauser, Pieternella J. Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N. Burggraaff, Marcel Nijland, Sanne H. Tonino, Anne I.J. Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong, Anton Hagenbeek
Publikováno v:
Haematologica, Vol 106, Iss 4 (2020)
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
Externí odkaz:
https://doaj.org/article/4d92849800704d5a8879878670f84aeb
Autor:
Cornelia AM Almekinders, Tessa G Steenbruggen, Ingrid A. Mandjes, Marta Lopez-Yurda, Monique EMM Bos, Terry G Wiersma, Gabe S. Sonke
Publikováno v:
Cancer Research. 83:OT2-15
Background Patients with metastatic breast cancer (MBC) are usually treated with palliative systemic therapy until progression or unacceptable toxicity. When progression occurs, clinicians typically switch to the next line of systemic therapy. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4e49b6156e2f087447c1ddc5f4092a7
https://doi.org/10.1158/1538-7445.sabcs22-ot2-15-01
https://doi.org/10.1158/1538-7445.sabcs22-ot2-15-01
Autor:
Brigit M. Aarts, Fernando M. Gomez, Marta Lopez-Yurda, Rob F. M. Bevers, Joris Herndriks, Regina G. H. Beets-Tan, Axel Bex, Elisabeth G. Klompenhouwer, Rutger W. van der Meer
Publikováno v:
European Radiology, 33(2), 1040-1049. Springer, Cham
European Radiology. SPRINGER
European Radiology
European Radiology. SPRINGER
European Radiology
Objectives Percutaneous radiofrequency ablation (RFA) is stated as a treatment option for renal cell carcinoma (RCC) smaller than 4 cm (T1a). Microwave ablation (MWA) is a newer technique and is still considered experimental in some guidelines. The o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be059f06dcb817f0369827e4fec81731
https://cris.maastrichtuniversity.nl/en/publications/6501e0ad-3b0f-4403-82cd-e3e2101cdbe5
https://cris.maastrichtuniversity.nl/en/publications/6501e0ad-3b0f-4403-82cd-e3e2101cdbe5
Autor:
Irene L.M. Reijers, Disha Rao, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W. Wouters, Andrew J. Spillane, Willem M.C. Klop, Annegien Broeks, Linda J.W. Bosch, Marta Lopez-Yurda, Winan J. van Houdt, Robert V. Rawson, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Jasper Bouwman, Joyce Sanders, Elsemieke Plasmeijer, Yannick S. Elshot, Richard A. Scolyer, Bart A. van de Wiel, Daniel S. Peeper, Alexander C.J. van Akkooi, Georgina V. Long, Christian U. Blank
Publikováno v:
Reijers, I L M, Rao, D, Versluis, J M, Menzies, A M, Dimitriadis, P, Wouters, M W, Spillane, A J, Klop, W M C, Broeks, A, Bosch, L J W, Lopez-Yurda, M, van Houdt, W J, Rawson, R V, Grijpink-Ongering, L G, Gonzalez, M, Cornelissen, S, Bouwman, J, Sanders, J, Plasmeijer, E, Elshot, Y S, Scolyer, R A, van de Wiel, B A, Peeper, D S, van Akkooi, A C J, Long, G V & Blank, C U 2023, ' IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma ', Journal of Experimental Medicine, vol. 220, no. 5, e20221952 . https://doi.org/10.1084/jem.20221952
Journal of experimental medicine, 220(5):e20221952. Rockefeller University Press
Journal of Experimental Medicine, 220(5):e20221952. Rockefeller University Press
Journal of experimental medicine, 220(5):e20221952. Rockefeller University Press
Journal of Experimental Medicine, 220(5):e20221952. Rockefeller University Press
Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deace
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17999c5aac89a5332bee79a05cb4e596
https://doi.org/10.1084/jem.20221952
https://doi.org/10.1084/jem.20221952
Autor:
Rick, Admiraal, Stefan, Nierkens, Marc B, Bierings, Robbert G M, Bredius, Ineke, van Vliet, Yilin, Jiang, Marta, Lopez-Yurda, A Birgitta, Versluijs, C Michel, Zwaan, Caroline A, Lindemans, Jaap Jan, Boelens
Publikováno v:
The Lancet Haematology, 9(2), e111-e120. Lancet Publishing Group
Background: Anti-thymocyte globulin, which is used in the conditioning of haematopoietic stem-cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD) and graft failure, has highly variable pharmacokinetics. Overexposure to anti-thymoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41c9f6d5007004ab5ec065beb7dfc0d
https://doi.org/10.1016/s2352-3026(21)00375-6
https://doi.org/10.1016/s2352-3026(21)00375-6